TW200829698A - Lipase variants for pharmaceutical use - Google Patents
Lipase variants for pharmaceutical use Download PDFInfo
- Publication number
- TW200829698A TW200829698A TW096148377A TW96148377A TW200829698A TW 200829698 A TW200829698 A TW 200829698A TW 096148377 A TW096148377 A TW 096148377A TW 96148377 A TW96148377 A TW 96148377A TW 200829698 A TW200829698 A TW 200829698A
- Authority
- TW
- Taiwan
- Prior art keywords
- lipase
- seq
- amino acid
- enzyme
- activity
- Prior art date
Links
- 108090001060 Lipase Proteins 0.000 title claims abstract description 240
- 102000004882 Lipase Human genes 0.000 title claims abstract description 240
- 239000004367 Lipase Substances 0.000 title claims abstract description 239
- 235000019421 lipase Nutrition 0.000 title claims abstract description 239
- 150000001413 amino acids Chemical class 0.000 claims abstract description 56
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 50
- 108091005804 Peptidases Proteins 0.000 claims abstract description 27
- 239000004365 Protease Substances 0.000 claims abstract description 27
- 239000003833 bile salt Substances 0.000 claims abstract description 26
- 230000029087 digestion Effects 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 21
- 102000057297 Pepsin A Human genes 0.000 claims abstract description 19
- 108090000284 Pepsin A Proteins 0.000 claims abstract description 19
- 229940111202 pepsin Drugs 0.000 claims abstract description 19
- 239000004382 Amylase Substances 0.000 claims abstract description 18
- 102000013142 Amylases Human genes 0.000 claims abstract description 18
- 108010065511 Amylases Proteins 0.000 claims abstract description 18
- 235000019418 amylase Nutrition 0.000 claims abstract description 18
- 238000000338 in vitro Methods 0.000 claims abstract description 17
- 230000001079 digestive effect Effects 0.000 claims abstract description 9
- 201000003883 Cystic fibrosis Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 208000035475 disorder Diseases 0.000 claims abstract description 7
- 206010033645 Pancreatitis Diseases 0.000 claims abstract description 6
- 208000035467 Pancreatic insufficiency Diseases 0.000 claims abstract description 5
- 238000006731 degradation reaction Methods 0.000 claims abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 4
- 102220479102 CD59 glycoprotein_N33Q_mutation Human genes 0.000 claims description 1609
- 102220097791 rs201753350 Human genes 0.000 claims description 549
- 102220598657 5-hydroxytryptamine receptor 1E_D27R_mutation Human genes 0.000 claims description 270
- 102220104423 rs63749907 Human genes 0.000 claims description 141
- 102220606460 C-reactive protein_G163V_mutation Human genes 0.000 claims description 100
- 102220052839 rs73113102 Human genes 0.000 claims description 94
- 102220254290 rs1553156175 Human genes 0.000 claims description 71
- 102220257095 rs587779102 Human genes 0.000 claims description 63
- 238000006467 substitution reaction Methods 0.000 claims description 55
- 102200108133 rs201753350 Human genes 0.000 claims description 51
- 102220105300 rs879254420 Human genes 0.000 claims description 48
- 229910052727 yttrium Inorganic materials 0.000 claims description 35
- 102220056648 rs730881059 Human genes 0.000 claims description 34
- 102220021416 rs80357110 Human genes 0.000 claims description 29
- 229910052720 vanadium Inorganic materials 0.000 claims description 27
- 102000035195 Peptidases Human genes 0.000 claims description 26
- 235000005911 diet Nutrition 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 23
- 108090000790 Enzymes Proteins 0.000 claims description 23
- 102220475917 Oligophrenin-1_G91V_mutation Human genes 0.000 claims description 23
- 230000037213 diet Effects 0.000 claims description 23
- 229940088598 enzyme Drugs 0.000 claims description 23
- 102200101939 rs72554338 Human genes 0.000 claims description 23
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 102220412429 c.297A>C Human genes 0.000 claims description 21
- 229910052698 phosphorus Inorganic materials 0.000 claims description 21
- 229910052721 tungsten Inorganic materials 0.000 claims description 20
- 235000019626 lipase activity Nutrition 0.000 claims description 19
- 102220105121 rs150066950 Human genes 0.000 claims description 19
- 102220083998 rs551990619 Human genes 0.000 claims description 18
- 230000006872 improvement Effects 0.000 claims description 17
- 102220487741 Protein eyes shut homolog_D27N_mutation Human genes 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 102200110982 rs28931568 Human genes 0.000 claims description 15
- 102220041676 rs587779102 Human genes 0.000 claims description 15
- 102220020884 rs80356880 Human genes 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 102220276634 rs1553131563 Human genes 0.000 claims description 14
- 102220536108 Serine/threonine-protein kinase OSR1_K46M_mutation Human genes 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 102200121669 rs104894915 Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 102220552927 Fidgetin-like protein 1_G163H_mutation Human genes 0.000 claims description 11
- 102220564804 Killer cell immunoglobulin-like receptor 2DL2_N73D_mutation Human genes 0.000 claims description 11
- 102220593678 Stromal interaction molecule 1_E87Q_mutation Human genes 0.000 claims description 11
- 102220245301 rs1555596673 Human genes 0.000 claims description 11
- 102200027496 rs63751429 Human genes 0.000 claims description 11
- 102220330013 rs78488639 Human genes 0.000 claims description 11
- 210000002784 stomach Anatomy 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 102220198277 rs1057519874 Human genes 0.000 claims description 10
- 102220204637 rs137852883 Human genes 0.000 claims description 10
- 102220045389 rs587782063 Human genes 0.000 claims description 10
- 102220360655 c.170A>G Human genes 0.000 claims description 9
- 102220536901 PRKC apoptosis WT1 regulator protein_L69I_mutation Human genes 0.000 claims description 8
- 235000021588 free fatty acids Nutrition 0.000 claims description 8
- 101150025207 VPK2 gene Proteins 0.000 claims description 7
- 101100049497 Variola virus (isolate Human/India/Ind3/1967) C14L gene Proteins 0.000 claims description 7
- 102200006121 rs1060501260 Human genes 0.000 claims description 7
- 102200131348 rs57983345 Human genes 0.000 claims description 7
- 102220059022 rs786201869 Human genes 0.000 claims description 7
- 102200158370 rs868333 Human genes 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 102220600976 Syndecan-4_N26A_mutation Human genes 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 102200158812 rs104894225 Human genes 0.000 claims description 6
- 102220082775 rs144148008 Human genes 0.000 claims description 6
- 102220184188 rs758665573 Human genes 0.000 claims description 6
- 102220087418 rs864622444 Human genes 0.000 claims description 6
- 102220104592 rs879254078 Human genes 0.000 claims description 6
- 102220524143 Cadherin-24_N26I_mutation Human genes 0.000 claims description 5
- 102220515651 Insulin-like growth factor I_R84E_mutation Human genes 0.000 claims description 5
- 102220593541 PMS1 protein homolog 1_N11D_mutation Human genes 0.000 claims description 5
- 102220474144 Phosphatidylcholine-sterol acyltransferase_T37M_mutation Human genes 0.000 claims description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 102200161847 rs104894126 Human genes 0.000 claims description 5
- 102200116704 rs77587352 Human genes 0.000 claims description 5
- 102220125026 rs886043836 Human genes 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 4
- 102200080817 rs104894869 Human genes 0.000 claims description 4
- 102200027488 rs63749907 Human genes 0.000 claims description 4
- 102220028139 rs80357084 Human genes 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 102220560906 Ataxin-2_N73Y_mutation Human genes 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 102220642119 Lipoma-preferred partner_D96R_mutation Human genes 0.000 claims description 3
- 102220508063 Mitochondrial folate transporter/carrier_G91R_mutation Human genes 0.000 claims description 3
- 102220526321 NHP2-like protein 1_G38K_mutation Human genes 0.000 claims description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 102220616017 Sterile alpha motif domain-containing protein 5_D96Y_mutation Human genes 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 235000011148 calcium chloride Nutrition 0.000 claims description 3
- 238000004364 calculation method Methods 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 102200102592 rs104893740 Human genes 0.000 claims description 3
- 102220229111 rs759454598 Human genes 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 102220600243 Cerebellin-2_N23Q_mutation Human genes 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 claims description 2
- 229920004890 Triton X-100 Polymers 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 231100000673 dose–response relationship Toxicity 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 102220057725 rs374836770 Human genes 0.000 claims 12
- 102220644676 Galectin-related protein_D96L_mutation Human genes 0.000 claims 7
- 239000000843 powder Substances 0.000 claims 5
- 102220473558 ADP-ribosylation factor-like protein 2-binding protein_E56A_mutation Human genes 0.000 claims 4
- 102220517768 Methyl-CpG-binding domain protein 3-like 2B_D27Y_mutation Human genes 0.000 claims 3
- 102220496421 Zinc finger CCHC domain-containing protein 24_E43V_mutation Human genes 0.000 claims 3
- 102220277043 rs1553408229 Human genes 0.000 claims 3
- 102220312400 rs1555802310 Human genes 0.000 claims 3
- 102200084990 rs199422124 Human genes 0.000 claims 3
- 102220568523 Clustered mitochondria protein homolog_E99S_mutation Human genes 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 102220500768 Protein N-lysine methyltransferase METTL21D_D96V_mutation Human genes 0.000 claims 2
- 102220363768 c.76A>C Human genes 0.000 claims 2
- 102200068777 rs1805005 Human genes 0.000 claims 2
- 102200097285 rs199473487 Human genes 0.000 claims 2
- 102220271537 rs200383861 Human genes 0.000 claims 2
- 102220041065 rs200979664 Human genes 0.000 claims 2
- 102200028671 rs3765620 Human genes 0.000 claims 2
- 102200006128 rs559848002 Human genes 0.000 claims 2
- 102200058234 rs80338731 Human genes 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108090000317 Chymotrypsin Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 101710084378 Lipase 2 Proteins 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
- 244000046052 Phaseolus vulgaris Species 0.000 claims 1
- 108091006629 SLC13A2 Proteins 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229960002376 chymotrypsin Drugs 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000028023 exocytosis Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims 1
- 102220099510 rs878853826 Human genes 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000002689 soil Substances 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
- 239000000052 vinegar Substances 0.000 claims 1
- 235000021419 vinegar Nutrition 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
- 229940093761 bile salts Drugs 0.000 abstract description 9
- 241000223258 Thermomyces lanuginosus Species 0.000 abstract description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229940040461 lipase Drugs 0.000 description 162
- 235000001014 amino acid Nutrition 0.000 description 39
- 229940024606 amino acid Drugs 0.000 description 37
- 239000000523 sample Substances 0.000 description 18
- 239000003925 fat Substances 0.000 description 13
- 235000019197 fats Nutrition 0.000 description 13
- 235000019419 proteases Nutrition 0.000 description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
- 235000003704 aspartic acid Nutrition 0.000 description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 241000223198 Humicola Species 0.000 description 4
- 102100023105 Sialin Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 102220279229 rs1554893808 Human genes 0.000 description 4
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 3
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102100037611 Lysophospholipase Human genes 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 102100035200 Phospholipase A and acyltransferase 4 Human genes 0.000 description 2
- 241000228341 Talaromyces Species 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- -1 1,1,3,3-tetramethylbutyl)-phenyl group Chemical group 0.000 description 1
- ZUPZIBXPMSNWDP-UHFFFAOYSA-N 2-(2,3-dihydroxypropoxy)ethyl-trimethylazanium Chemical compound C[N+](C)(C)CCOCC(O)CO ZUPZIBXPMSNWDP-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000223651 Aureobasidium Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical group CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000221207 Filobasidium Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 1
- 241000171741 Humicola fuscoatra Species 0.000 description 1
- 241000223199 Humicola grisea Species 0.000 description 1
- 241001350650 Humicola lutea Species 0.000 description 1
- 241001373560 Humicola sp. Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000017055 Lipoprotein Lipase Human genes 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 241001344133 Magnaporthe Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000226677 Myceliophthora Species 0.000 description 1
- 241000233892 Neocallimastix Species 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 102100027441 Nucleobindin-2 Human genes 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 241001236817 Paecilomyces <Clavicipitaceae> Species 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000235379 Piromyces Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000030452 Rasamsonia byssochlamydoides Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000222480 Schizophyllum Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000228178 Thermoascus Species 0.000 description 1
- 241000223257 Thermomyces Species 0.000 description 1
- 241001261109 Thermomyces ibadanensis Species 0.000 description 1
- 241000650705 Thermomyces verrucosus Species 0.000 description 1
- 241001494489 Thielavia Species 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- YKHUTMGNPUIXEN-UHFFFAOYSA-N [Ru].[O-][N+]#N Chemical group [Ru].[O-][N+]#N YKHUTMGNPUIXEN-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108010020132 microbial serine proteinases Proteins 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102220205885 rs1057524159 Human genes 0.000 description 1
- 102220022307 rs80357066 Human genes 0.000 description 1
- 102220095343 rs876660671 Human genes 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87119606P | 2006-12-21 | 2006-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200829698A true TW200829698A (en) | 2008-07-16 |
Family
ID=38043020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096148377A TW200829698A (en) | 2006-12-21 | 2007-12-18 | Lipase variants for pharmaceutical use |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8273348B2 (enExample) |
| EP (6) | EP2455461B1 (enExample) |
| JP (1) | JP5406040B2 (enExample) |
| KR (1) | KR20090101930A (enExample) |
| CN (2) | CN105112386A (enExample) |
| AR (1) | AR064494A1 (enExample) |
| AU (1) | AU2007337150A1 (enExample) |
| BR (1) | BRPI0721103A2 (enExample) |
| CA (3) | CA2961041C (enExample) |
| IL (1) | IL198893A0 (enExample) |
| MX (1) | MX2009006597A (enExample) |
| NO (1) | NO20092729L (enExample) |
| RU (1) | RU2009128067A (enExample) |
| TW (1) | TW200829698A (enExample) |
| WO (1) | WO2008079685A2 (enExample) |
| ZA (1) | ZA200903598B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5032300B2 (ja) | 2004-03-22 | 2012-09-26 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物 |
| EP2278002B1 (en) | 2005-07-29 | 2017-07-12 | Abbott Laboratories GmbH | Pancreatin with reduced viral content |
| US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
| US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
| US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
| WO2008079685A2 (en) * | 2006-12-21 | 2008-07-03 | Novozymes A/S | Lipase variants for pharmaceutical use |
| JP2011513539A (ja) * | 2008-02-29 | 2011-04-28 | ザ プロクター アンド ギャンブル カンパニー | リパーゼを含む洗剤組成物 |
| MX2010009464A (es) | 2008-02-29 | 2010-09-22 | Dsm Ip Assets Bv | Lipasas con alta especificidad hacia acidos grasos de cadena corta y usos de las mismas. |
| EP2250258B1 (en) * | 2008-02-29 | 2017-01-04 | Novozymes A/S | Lipolytic enzyme variant with improved stability and polynucleotides encoding same |
| CA2782613C (en) | 2009-12-09 | 2016-08-23 | The Procter & Gamble Company | Fabric and home care products |
| US20140147895A1 (en) | 2011-07-22 | 2014-05-29 | Novozymes A/S | Processes for Pretreating Cellulosic Material and Improving Hydrolysis Thereof |
| US8268305B1 (en) | 2011-09-23 | 2012-09-18 | Bio-Cat, Inc. | Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase |
| ES2680145T3 (es) * | 2011-12-29 | 2018-09-04 | Novozymes A/S | Composiciones detergentes con variantes de lipasa |
| US9394530B2 (en) * | 2012-02-03 | 2016-07-19 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| WO2013149858A1 (en) | 2012-04-02 | 2013-10-10 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| CA2887898A1 (en) * | 2012-10-12 | 2014-04-17 | Danisco Us Inc. | Compositions and methods comprising a lipolytic enzyme variant |
| CN115521831A (zh) * | 2013-05-14 | 2022-12-27 | 诺维信公司 | 洗涤剂组合物 |
| ES2956266T3 (es) * | 2013-07-19 | 2023-12-18 | Danisco Us Inc | Composiciones y procedimientos que comprenden una variante de enzima lipolítica |
| EP3221447A1 (en) * | 2014-11-20 | 2017-09-27 | Novozymes A/S | Alicyclobacillus variants and polynucleotides encoding same |
| US10457921B2 (en) | 2014-12-05 | 2019-10-29 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| MX382218B (es) * | 2014-12-09 | 2025-03-13 | Novozymes As | Variantes de lipasa y polinucleotidos que las codifican. |
| EP3280818A2 (en) | 2015-04-07 | 2018-02-14 | Novozymes A/S | Methods for selecting enzymes having lipase activity |
| EP3317407B1 (en) * | 2015-07-01 | 2021-05-19 | Novozymes A/S | Methods of reducing odor |
| US10760037B2 (en) * | 2015-07-03 | 2020-09-01 | Novozymes A/S | Sulfite compositions |
| US11326152B2 (en) | 2016-07-18 | 2022-05-10 | Novozymes A/S | Lipase variants, polynucleotides encoding same and the use thereof |
| JP7081767B2 (ja) * | 2017-01-30 | 2022-06-07 | 学校法人日本医科大学 | アデノ随伴ウイルス（ａａｖ）キャプシドタンパク質の変異体 |
| MX2020003779A (es) * | 2017-09-27 | 2020-08-03 | Procter & Gamble | Composiciones detergentes que comprenden lipasas. |
| JP7317811B2 (ja) * | 2017-09-27 | 2023-07-31 | ノボザイムス アクティーゼルスカブ | リパーゼ変異体及びかかるリパーゼ変異体を含むマイクロカプセル組成物 |
| WO2019154952A1 (en) * | 2018-02-08 | 2019-08-15 | Novozymes A/S | Lipase variants and compositions thereof |
| WO2020037100A1 (en) * | 2018-08-16 | 2020-02-20 | Isolere Bio, Inc. | Genetically encoded polypeptide for affinity capture and purification of biologics |
| CN111334369B (zh) * | 2020-03-11 | 2022-10-21 | 陕西科技大学 | 一种酶法制备卵磷脂型pufa的方法 |
| US12467042B2 (en) * | 2020-06-24 | 2025-11-11 | Dermapharm Aktiengesellschaft | Lipase enzyme |
| EP4237552A2 (en) * | 2020-10-29 | 2023-09-06 | Novozymes A/S | Lipase variants and compositions comprising such lipase variants |
| CN113846074B (zh) * | 2021-10-20 | 2022-10-21 | 南京林业大学 | 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用 |
| AU2023272468A1 (en) | 2022-05-14 | 2024-11-14 | Novonesis Plant Biosolutions A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
| CN119522274A (zh) * | 2022-06-24 | 2025-02-25 | 诺维信公司 | 脂肪酶变体和包含这样的脂肪酶变体的组合物 |
| CN120082537A (zh) * | 2023-12-01 | 2025-06-03 | 青岛蔚蓝生物集团有限公司 | 一种脂肪酶突变体 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK173590D0 (da) | 1990-06-06 | 1990-07-19 | Novo Nordisk As | Rekombinante terapeutiske lipaser |
| DK46693D0 (enExample) | 1993-04-23 | 1993-04-23 | Novo Nordisk As | |
| US5869438A (en) | 1990-09-13 | 1999-02-09 | Novo Nordisk A/S | Lipase variants |
| JP3469234B2 (ja) * | 1990-09-13 | 2003-11-25 | ノボザイムス アクティーゼルスカブ | リパーゼ変異体 |
| DE69130113T2 (de) | 1990-12-05 | 1999-05-12 | Novo Nordisk A/S, Bagsvaerd | Proteine mit geänderten epitopen und verfahren zur deren herstellung |
| ATE169678T1 (de) | 1991-05-01 | 1998-08-15 | Novo Nordisk As | Stabilisierte enzyme |
| DK39693D0 (da) | 1993-04-02 | 1993-04-02 | Novo Nordisk As | Enzym |
| BR9407752A (pt) | 1993-10-04 | 1997-03-04 | Novo Nordisk As | Preparaçao de enzima aditivo detergente composiçao detergente processo para o tratamento de fibras lignocelulósicas |
| AU1806795A (en) | 1994-02-22 | 1995-09-04 | Novo Nordisk A/S | A method of preparing a variant of a lipolytic enzyme |
| JPH10509324A (ja) | 1994-11-24 | 1998-09-14 | ノボ ノルディスク アクティーゼルスカブ | 抑制されたアレルゲン性を有するポリペプチドの製造のための方法 |
| AU697440B2 (en) | 1994-12-07 | 1998-10-08 | Novozymes A/S | Polypeptide with reduced allergenicity |
| CA2209617C (en) | 1995-01-26 | 2002-05-28 | Novo Nordisk A/S | Animal feed additives comprising xylanase |
| WO1997004079A1 (en) | 1995-07-14 | 1997-02-06 | Novo Nordisk A/S | A modified enzyme with lipolytic activity |
| US6495357B1 (en) * | 1995-07-14 | 2002-12-17 | Novozyme A/S | Lipolytic enzymes |
| CN1192780B (zh) | 1995-08-11 | 2010-08-04 | 诺沃奇梅兹有限公司 | 新的脂解酶 |
| JP2002510963A (ja) | 1997-01-10 | 2002-04-09 | ノボザイムス アクティーゼルスカブ | スキンケア用酵素修飾体 |
| JP2001511162A (ja) | 1997-02-06 | 2001-08-07 | ノボ ノルディスク アクティーゼルスカブ | 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体 |
| JP2002516615A (ja) | 1997-06-25 | 2002-06-04 | ノボザイムス アクティーゼルスカブ | 変性ポリペプチド |
| ATE328070T1 (de) * | 1998-02-17 | 2006-06-15 | Novozymes As | Lipasevariante |
| AU3247699A (en) | 1998-02-17 | 1999-09-06 | Novo Nordisk A/S | Lipase variant |
| WO2000022103A1 (en) | 1998-10-13 | 2000-04-20 | Novozymes A/S | A modified polypeptide with reduced immune response |
| DE69938435D1 (de) | 1998-10-30 | 2008-05-08 | Novozymes As | Niedrigallergene Proteinvarianten |
| CA2348822A1 (en) | 1998-10-30 | 2000-05-11 | Novozymes A/S | Glycosylated proteins having reduced allergenicity |
| EP1131416B1 (en) | 1998-11-27 | 2009-09-02 | Novozymes A/S | Lipolytic enzyme variants |
| US7312062B2 (en) * | 1998-11-27 | 2007-12-25 | Novozymes A/S | Lipolytic enzyme variants |
| TR200102784T2 (tr) | 1999-03-17 | 2002-04-22 | Solvay Pharmaceuticals Gmbh | Diyabet tedavisi için ilaç |
| EP1171581A1 (en) * | 1999-03-31 | 2002-01-16 | Novozymes A/S | Lipase variant |
| EP2278000A1 (en) * | 1999-03-31 | 2011-01-26 | Novozymes A/S | Lipase variant |
| WO2001058276A2 (en) | 2000-02-08 | 2001-08-16 | F Hoffmann-La Roche Ag | Use of acid-stable proteases in animal feed |
| WO2001083761A1 (en) | 2000-04-28 | 2001-11-08 | Novozymes A/S | Laccase mutants |
| DE60231700D1 (de) * | 2001-01-10 | 2009-05-07 | Novozymes As | Variante eines lipolytischen enzyms |
| AR032392A1 (es) | 2001-01-19 | 2003-11-05 | Solvay Pharm Gmbh | Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado. |
| CN1491278A (zh) | 2001-02-07 | 2004-04-21 | ŵά�Ź�˾ | 脂酶变体 |
| EP1468084A1 (en) * | 2002-01-16 | 2004-10-20 | Novozymes A/S | Lipolytic enzyme variants and method for their production |
| JP2007506405A (ja) | 2003-02-06 | 2007-03-22 | ノボザイムス アクティーゼルスカブ | 糸状菌におけるヒトｈ鎖抗体の発現 |
| EP2270139B1 (en) * | 2003-05-09 | 2016-07-27 | Novozymes A/S | Variant lipolytic enzymes |
| US20060236414A1 (en) | 2003-06-19 | 2006-10-19 | Novozymes A/S | Proteases and methods for producing them |
| EP1639102A2 (en) * | 2003-06-19 | 2006-03-29 | Novozymes A/S | Phospholipase variants |
| AR047440A1 (es) | 2004-01-21 | 2006-01-18 | Novozymes As | Produccion de un anticuerpo monoclonal en un hongo heterocarion o una celula huesped fungal |
| JP5032300B2 (ja) | 2004-03-22 | 2012-09-26 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物 |
| DK1809320T3 (da) | 2004-10-14 | 2010-11-15 | Cystic Fibrosis Foundation The | Præparater indeholdende lipase, protease og amylase til behandling af pankreatisk insufficiens |
| US20080138856A1 (en) | 2005-02-10 | 2008-06-12 | Novozymes A/S | Enzymatic Enantioselective Ester or Amide Hydrolysis or Synthesis |
| KR20080017025A (ko) * | 2005-06-24 | 2008-02-25 | 노보자임스 에이/에스 | 약학적 용도의 리파제 |
| MX2007015471A (es) | 2005-06-24 | 2008-04-04 | Novozymes As | Amilasas para uso farmaceutico. |
| JP2008546395A (ja) | 2005-06-24 | 2008-12-25 | ノボザイムス アクティーゼルスカブ | 医薬使用のためのプロテアーゼ |
| WO2007080197A2 (en) * | 2006-01-16 | 2007-07-19 | Novozymes A/S | Immobilised enzymes |
| CN105296445B (zh) * | 2006-01-23 | 2022-05-10 | 诺维信公司 | 脂肪酶变体 |
| CA2635927A1 (en) * | 2006-01-23 | 2007-08-02 | The Procter And Gamble Company | A composition comprising a lipase and a bleach catalyst |
| WO2008079685A2 (en) * | 2006-12-21 | 2008-07-03 | Novozymes A/S | Lipase variants for pharmaceutical use |
-
2007
- 2007-12-12 WO PCT/US2007/087168 patent/WO2008079685A2/en not_active Ceased
- 2007-12-12 EP EP12155317.6A patent/EP2455461B1/en active Active
- 2007-12-12 EP EP10172609.9A patent/EP2261328B1/en active Active
- 2007-12-12 CN CN201510504893.8A patent/CN105112386A/zh active Pending
- 2007-12-12 EP EP12155315A patent/EP2455460A3/en not_active Withdrawn
- 2007-12-12 MX MX2009006597A patent/MX2009006597A/es not_active Application Discontinuation
- 2007-12-12 JP JP2009543078A patent/JP5406040B2/ja active Active
- 2007-12-12 BR BRPI0721103-1A patent/BRPI0721103A2/pt not_active IP Right Cessation
- 2007-12-12 CA CA2961041A patent/CA2961041C/en active Active
- 2007-12-12 CA CA2670643A patent/CA2670643C/en active Active
- 2007-12-12 US US12/519,868 patent/US8273348B2/en active Active
- 2007-12-12 KR KR1020097014850A patent/KR20090101930A/ko not_active Withdrawn
- 2007-12-12 EP EP07869130A patent/EP2099907A2/en not_active Withdrawn
- 2007-12-12 EP EP12155294.7A patent/EP2455459B1/en active Active
- 2007-12-12 EP EP12155319.2A patent/EP2455462B1/en active Active
- 2007-12-12 CN CN200780051638.6A patent/CN101743308B/zh active Active
- 2007-12-12 CA CA3081308A patent/CA3081308C/en active Active
- 2007-12-12 RU RU2009128067/10A patent/RU2009128067A/ru not_active Application Discontinuation
- 2007-12-12 AU AU2007337150A patent/AU2007337150A1/en not_active Abandoned
- 2007-12-18 TW TW096148377A patent/TW200829698A/zh unknown
- 2007-12-21 AR ARP070105859A patent/AR064494A1/es not_active Application Discontinuation
-
2009
- 2009-05-21 IL IL198893A patent/IL198893A0/en unknown
- 2009-05-25 ZA ZA200903598A patent/ZA200903598B/xx unknown
- 2009-07-20 NO NO20092729A patent/NO20092729L/no not_active Application Discontinuation
-
2012
- 2012-08-16 US US13/587,043 patent/US9029115B2/en active Active
-
2015
- 2015-04-06 US US14/679,563 patent/US9539311B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200829698A (en) | Lipase variants for pharmaceutical use | |
| US20090047266A1 (en) | Lipases for Pharmaceutical Use | |
| CZ20031900A3 (cs) | Směs mikrobiálních enzymů | |
| US8455235B2 (en) | Protease variants for pharmaceutical use | |
| AU2013203500B2 (en) | Lipase variants for pharmaceutical use | |
| AU2013200626B2 (en) | Lipase variants for pharmaceutical use | |
| HK1141553A (en) | Lipase variants for pharmaceutical use | |
| HK1145697A (en) | Protease variants for pharmaceutical use | |
| HK1113174A (en) | Lipases for pharmaceutical use |